Table 1.
Some examples on the effect of polyamidoamine (PAMAM) dendrimer surface modification on improvement of solubility, biodistribution, and targeted drug delivery of small molecules.
| PAMAM Formulation | Drug Loaded | Formulation Type | Effects Observed/Results | References |
|---|---|---|---|---|
| PEG-PAMAM-G4 | Silybin (1) | Encapsulation | High PEG increased solubility | [26] |
| FA-PAMAM | CDF (2) | Encapsulation | Increased solubility and targeted delivery of CDF | [27] |
| HA-PAMAM | CDF (2) | Encapsulation | Increased cellular uptake & reduced toxicity | [28] |
| PAMAM | Capecitabine (3) | Conjugation | Targeted delivery to tumor & less toxicity to cell | [29] |
| PAMAM-lipid hybrid | Paclitaxel (4) | Encapsulation | Increased solubility & activity | [30] |
| PAMAM-Biotin | SB-T-1214 (5) | Conjugation | High potency & targeted drug delivery | [31] |
| PAMAM-G4-DHA | Paclitaxel (6) | Conjugation | Increased activity in UGC treatment | [37] |
| G5-PAMAM-NH2-Se/siRNA | Cisplatin (6) | Encapsulation | Enhanced toxicity | [32] |
| G4-PAMAM-NH2 | TMScu (7) | Encapsultion | Increased solubility | [2] |
| G5-PAMAM-NH2-aptamers | CPT (8) | Encapsulation | Sustained release | [36] |
| Apt-PEG-PAMAM | CPT (8) | Encapsulation | Targeted drug delivery | [36] |
| G4-PAMAM-COOH | DOX (9) | Conjugation | Efficiency in treating lung metastasis | [38] |
| IL6-PAMAM-G4.5 | DOX (9) | Conjugation | Targeted delivery of DOX to cervical cancer cells | [39] |
| PAMAM-COOH/NH2 | 5-FU (10) | Encapsulation | Archieved high loading & low toxicity | [40] |
| PAMAM-NH2 | 5-FU (10) | Encapsulation | Improved solubility & bonding | [40] |
| PAMAM | Berberine (11) | Conjugation & Encapsulation | Improved pharmacokinetic profile | [41] |
| PAMAM | Gallic acid (12) | Conjugation | Improved bioavailability | [42] |
| PAMAM-G4 | Bendamustine (13) | Conjugation | Improved stability and pharmacokinetics | [43] |
| PAMAM-MSN | curcumin (14) | Encapsulation | Sustained release of curcumin for long time | [44] |
| Silica-PAMAM | BCA (15) | Encapsulation | Sustained release, less toxicity & enhanced activity | [45] |
| PAMAM-G0-lauroyl | NAP (16) | Conjugation | Increased solubility & low toxicity | [46] |
| PAMAM-hybrid | RAPL (18) & HCTZ (19) | Encapsulation | High solubility improvement | [47] |
| PAMAM-NH2/COOH/TRIS | Candesartan cilexetil (CC) (20) | Conjugation | anionic dendrimer enhanced solubility | [48] |
| PAMAM-G3 | DEX (21) | Encapsulation | Controlled release | [49] |
| PEG-PAMAM-NH2 | Triamcinole acetonide (TA) (22) | Conjugation | High level transgene expression | [50] |
| PAMAM | Amphotercin B (23) | Encapsulation | Increased solubility | [51] |
| PEG-PAMAM-G7 or 5/NLC | PB (24) | Encapsulation | Improved solubility & oral bioavailability | [52] |
| PEG-PAMAM-G5/7-NLC | Probuco (PB) (24) | Encapsulation | High oral bioavailability and activity | [52] |
| PAMAM-G4 | Rasveratrol (25) | Encapsulation | Improved solubility succeded for commercialization | [53] |